BIRAD – Research & Development Company Ltd. ’s Post

⭐ We’re delighted to share with you the recent publication from Professor B. E. B. Nwoke, Imo State University, on NTD mapping for effective programmes. This two-part presentation is the newest addition to the free to access series on Neglected Tropical Diseases. ▶ In this talk, Prof. Nwoke introduces the concept of disease mapping and highlights the importance of mapping for NTDs. He reviews the challenges which arise from the availability of preventative chemotherapy (PC) against NTDs and the diagnostic procedures that have been developed for mapping these diseases. Prof. Nwoke also discusses the procedures, techniques and guidelines for mapping of the following five PC-NTDS: onchocerciasis, loiasis (tropical eye worm), lymphatic filariasis, schistosomiasis (soil-transmitted helminths), and trachoma, and explores how new technologies have improved NTD mapping processes. 👇 For full access to Prof. Nwoke’s presentation as well as a host of others on NTDs within The Biomedical & Life Sciences Collection, please hit the link below. https://lnkd.in/empQs3X9  

😊 Delighted to share that our study on 𝐇𝐲𝐩𝐞𝐫𝐜𝐨𝐚𝐠𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐚𝐟𝐭𝐞𝐫 𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥 𝐃𝐢𝐬𝐜𝐡𝐚𝐫𝐠𝐞 𝐢𝐧 𝐀𝐜𝐮𝐭𝐞 𝐒𝐞𝐯𝐞𝐫𝐞 𝐔𝐥𝐜𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐂𝐨𝐥𝐢𝐭𝐢𝐬is now published in 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐆𝐚𝐬𝐭𝐫𝐨𝐞𝐧𝐭𝐞𝐫𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐇𝐞𝐩𝐚𝐭𝐨𝐥𝐨𝐠𝐲. Special thanks to the mentorship of 𝑷𝒓𝒐𝒇𝒆𝒔𝒔𝒐𝒓 Vipul Jairath ✍ 𝑲𝒆𝒚 𝒇𝒊𝒏𝒅𝒊𝒏𝒈𝒔: 𝐏𝐞𝐫𝐬𝐢𝐬𝐭𝐞𝐧𝐭 𝐑𝐢𝐬𝐤: Patients with acute severe ulcerative colitis (ASUC) exhibited a hypercoagulable profile not only at admission but also up to 12 weeks post-discharge, highlighting an extended risk of venous thromboembolism (VTE). 𝐂𝐨𝐦𝐩𝐚𝐫𝐢𝐬𝐨𝐧 𝐰𝐢𝐭𝐡 𝐂𝐨𝐧𝐭𝐫𝐨𝐥𝐬: Compared to patients with quiescent ulcerative colitis, those with ASUC demonstrated significantly higher thrombin potential and clot firmness, indicating a pronounced pro-thrombotic state. ✍ 𝐂𝐨𝐧𝐜𝐥𝐮𝐬𝐢𝐨𝐧: These observations underscore the elevated risk of VTE post-hospital discharge in patients with ASUC. https://lnkd.in/gxehxEPx

Anticipated NIH funding opportunities to investigate infection-associated chronic conditions and illnesses have been published! These are first of a kind, exciting opportunities for researchers studying POTS, PANDAS, ME/CFS, post-treatment Lyme disease, Long COVID, and MCAS. 🔵 PAR-25-115 Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional) https://lnkd.in/eP52vi-B 🔵 PAR-25-116 Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional) https://lnkd.in/edzT3ZsD ▶ For reference see previous post below: I am beyond pleased to see the recent Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional). The Background for the Research Initiative Details includes PANDAS among several prevalent chronic illnesses that have long been suspected to have an infectious trigger in a certain subset of individuals. The recognition of this often neglected group of patients is outstanding progress. https://lnkd.in/e8vVwFmi The Louisa Adelynn Johnson Fund for Complex Disease Amanda Crowley Sheilah Gauch, LICSW, M.Ed Monika Cheney Bibiana C. Wendy Nawara, MSW, BCPA Ramesh Hamadani - Allen Anna Conkey Susan Newman Manfull, PhD #POTS #PANS #dysautonomia

🚨 New publication We want to share the most recent publication of our group. In this paper we estimated the prevalence of sarcopenia in hospitalized older adults using different approaches. Also, we explore the relevance of other variables (clinical, biomarkers, and body composition) to classify better the hospitalized older adults. Three important messages: 1️⃣ Sarcopenia is highly prevalent in hospitalized older adults. From 7.3 to 31.6%, depending on the approach used. 2️⃣ The agreement between approaches was low, both sarcopenia and severe sarcopenia. 3️⃣ Three different kind of patients was found: 1. subjects with good muscle mass, good physical performance, and low fat mass; 2. subjects with good muscle mass, intermediate physical performance, and high fat mass; 3. low muscle mass, low physical performance, and low fat mass. Méderi Escuela de Medicina y Ciencias de la Salud - Universidad del Rosario Luisa Fernanda MURCIA Miguel G. Borda

In June, a groundbreaking study published in Nature Medicine brought two important firsts for Parkinson’s disease, an area long in need of better diagnostics and treatments. Here’s what has researchers excited: ➡ A diagnostic test that detects abnormal alpha-synuclein in cerebrospinal fluid. ➡ An immune-based treatment, similar to a vaccine, that trains the immune system to target misfolded proteins. The ability to measure these proteins has been a key focus in Parkinson’s research for years, making this a significant milestone. This article from TIME Magazine explores how the test and vaccine work, the journey to these discoveries, and what this could mean for future diagnostics and treatments for Parkinson’s disease. Read it here: bit.ly/4gZlqs6

⏰ FINAL REMINDER: The Rare Bone Disease Alliance is hosting the fourth Rare Bone Disease Alliance Scientific Symposium on November 21, with this session focused on fibrodysplasia ossificans progressiva (FOP). Among rare diseases, the FOP research space is one of the most active and exciting 🧬 With the first-ever treatment for FOP approved in select countries and five active FOP clinical trials, there is still an abundance of preclinical research with the potential to be translated into safe and effective new medicines. In this “deep dive” into FOP, you’ll hear from researchers and experts at the University of Pennsylvania, Massachusetts General Hospital & Harvard Medical School, Amsterdam University Medical Center, Children's Mercy Hospital and the IFOPA 🙌 🩺🔬 This Scientific Symposium is designed for researchers and doctors interested in rare bone diseases. 📌 REGISTER HERE FOR THIS VIRTUAL EVENT: https://lnkd.in/gyrM_Yr8

In June, a groundbreaking study published in Nature Medicine brought two important firsts for Parkinson’s disease, an area long in need of better diagnostics and treatments. Here’s what has researchers excited: ➡ A diagnostic test that detects abnormal alpha-synuclein in cerebrospinal fluid. ➡ An immune-based treatment, similar to a vaccine, that trains the immune system to target misfolded proteins. The ability to measure these proteins has been a key focus in Parkinson’s research for years, making this a significant milestone. This article from TIME Magazine explores how the test and vaccine work, the journey to these discoveries, and what this could mean for future diagnostics and treatments for Parkinson’s disease. Read it here: https://lnkd.in/edtwA2_P

🧑🔬🏆 5 Principal Investigators from the Champalimaud Foundation, GIMM and i3S have been awarded funding from the #CaixaResearch Health Call 2024! 👏 With support from “la Caixa” Foundation, these scientists will advance groundbreaking research on #metastasis dormancy, #immunesystem responses to diseases, #hostpathogen interactions, and #tuberculosis treatment 🔬🧬🧪 Ana Luísa Correia from the Champalimaud Foundation will explore how #breastcancer cells enter a state of dormancy 💤 and reactivate years later, causing metastasis. The research aims to design therapies 💊 that prevent this reactivation ✋, focusing on the liver and bone. This project is in collaboration with Neta Erez from Tel Aviv University and co-funded by FCT 💪 Learn more about their projects here! 👉 https://lnkd.in/dDAtRCAh Ana Correia GIMM i3S - Instituto de Investigação e Inovação em Saúde Fundación ”la Caixa” #CaixaResearch

In June, a groundbreaking study published in Nature Medicine brought two important firsts for Parkinson’s disease, an area long in need of better diagnostics and treatments. Here’s what has researchers excited: ➡ A diagnostic test that detects abnormal alpha-synuclein in cerebrospinal fluid. ➡ An immune-based treatment, similar to a vaccine, that trains the immune system to target misfolded proteins. The ability to measure these proteins has been a key focus in Parkinson’s research for years, making this a significant milestone. This article from TIME Magazine explores how the test and vaccine work, the journey to these discoveries, and what this could mean for future diagnostics and treatments for Parkinson’s disease. Read it here: https://lnkd.in/danFaMQs

Great news👍! Judith Rosmalen has received a €1.4 million grant from ZonMw for her research ‘Unravelling post-COVID: variability and biological basis’. The aim of her research is to gain more knowledge and insight into the underlying mechanisms involved in post-COVID. Post-COVID affects 1 in 8 people after SARS-CoV-2 infection, and leads to high personal and societal costs. How post-COVID occurs is unclear🤷♀️. The aim of this study is to unravel post-COVID heterogeneity in the Lifelines_NL cohort, with data and biomaterials collected before, during and after the pandemic. The project will compare participants with post-COVID with those who recovered after COVID-19. To investigate heterogeneity in post-COVID, the dataset will be enriched with immune and metabolic measurements while using two approaches. First, the project will define subtypes of post-COVID based on symptoms. This top-down approach is in line with clinical practice and can help in better diagnosis and treatment. Second, using advanced data analysis, the project will identify subtypes of post-COVID patients based on biomarker profiles. This bottom-up approach increases the understanding of the onset of post-COVID, possibly leading to new treatment options. #postcovid